99 related articles for article (PubMed ID: 17977555)
1. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
2. Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.
Hu G; Ma A; Dou X; Zhao L; Wang J
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240358
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Clemente JC; Coman RM; Thiaville MM; Janka LK; Jeung JA; Nukoolkarn S; Govindasamy L; Agbandje-McKenna M; McKenna R; Leelamanit W; Goodenow MM; Dunn BM
Biochemistry; 2006 May; 45(17):5468-77. PubMed ID: 16634628
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.
Prabu-Jeyabalan M; Nalivaika EA; Romano K; Schiffer CA
J Virol; 2006 Apr; 80(7):3607-16. PubMed ID: 16537628
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
Altman MD; Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Chellappan S; Kairys V; Fernandes MX; Gilson MK; Schiffer CA; Rana TM; Tidor B
J Am Chem Soc; 2008 May; 130(19):6099-113. PubMed ID: 18412349
[TBL] [Abstract][Full Text] [Related]
6. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Velazquez-Campoy A; Todd MJ; Vega S; Freire E
Proc Natl Acad Sci U S A; 2001 May; 98(11):6062-7. PubMed ID: 11353856
[TBL] [Abstract][Full Text] [Related]
7. Crucial stages of protein folding through a solvable model: predicting target sites for enzyme-inhibiting drugs.
Micheletti C; Cecconi F; Flammini A; Maritan A
Protein Sci; 2002 Aug; 11(8):1878-87. PubMed ID: 12142442
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments.
Ding F; Layten M; Simmerling C
J Am Chem Soc; 2008 Jun; 130(23):7184-5. PubMed ID: 18479129
[TBL] [Abstract][Full Text] [Related]
9. Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.
Khan SN; Persons JD; Paulsen JL; Guerrero M; Schiffer CA; Kurt-Yilmaz N; Ishima R
Biochemistry; 2018 Mar; 57(10):1652-1662. PubMed ID: 29457713
[TBL] [Abstract][Full Text] [Related]
10. The early years of retroviral protease crystal structures.
Miller M
Biopolymers; 2010; 94(4):521-9. PubMed ID: 20593466
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor-induced conformational shifts and ligand-exchange dynamics for HIV-1 protease measured by pulsed EPR and NMR spectroscopy.
Huang X; de Vera IM; Veloro AM; Blackburn ME; Kear JL; Carter JD; Rocca JR; Simmerling C; Dunn BM; Fanucci GE
J Phys Chem B; 2012 Dec; 116(49):14235-44. PubMed ID: 23167829
[TBL] [Abstract][Full Text] [Related]
12. Evolution under Drug Pressure Remodels the Folding Free-Energy Landscape of Mature HIV-1 Protease.
Louis JM; Roche J
J Mol Biol; 2016 Jul; 428(13):2780-92. PubMed ID: 27170547
[TBL] [Abstract][Full Text] [Related]
13. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
Xie L; Evangelidis T; Xie L; Bourne PE
PLoS Comput Biol; 2011 Apr; 7(4):e1002037. PubMed ID: 21552547
[TBL] [Abstract][Full Text] [Related]
14. A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.
Windsor IW; Raines RT
Acta Crystallogr D Struct Biol; 2018 Jul; 74(Pt 7):690-694. PubMed ID: 29968678
[TBL] [Abstract][Full Text] [Related]
15. HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.
Sheik Ismail Z; Worth R; Mosebi S; Sayed Y
Protein J; 2023 Oct; 42(5):490-501. PubMed ID: 37421557
[TBL] [Abstract][Full Text] [Related]
16. Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution.
Özer N; Özen A; Schiffer CA; Haliloğlu T
Evol Appl; 2015 Feb; 8(2):185-98. PubMed ID: 25685193
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
18. Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
Ghosh AK; Mishevich JL; Kovela S; Shaktah R; Ghosh AK; Johnson M; Wang YF; Wong-Sam A; Agniswamy J; Amano M; Takamatsu Y; Hattori SI; Weber IT; Mitsuya H
Eur J Med Chem; 2023 Jul; 255():115385. PubMed ID: 37150084
[TBL] [Abstract][Full Text] [Related]
19. Viral proteases as therapeutic targets.
Majerová T; Konvalinka J
Mol Aspects Med; 2022 Dec; 88():101159. PubMed ID: 36459838
[TBL] [Abstract][Full Text] [Related]
20. Different Mutation Tolerance of Lentiviral (HIV-1) and Deltaretroviral (BLV and HTLV) Protease Precursors.
Mótyán JA; Kassay N; Matúz K; Tőzsér J
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
